| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Herpes Simplex Virus 1 (IgG), Type-Specific Antibody : 3636
Test CodeHSV1GG or 3636
Alias/See Also
Herpes 1 IgG Ab, Herpes 1 IgG Serum, Herpes IgG 1, Herpes Type 1 Specific Antibody, HSV 1 IgG
CPT Codes
86695
Instructions
Serum separator tube (gold top preferred) or a plain red top tube.
Transport Container
Centrifuge the serum separator tube and transport; if a plain red top tube, centrifuge and aliquot 1 mL serum (Min. 0.5 mL) into a standard transport tube.
Transport Temperature
Refrigerated.
Specimen Stability
After separation from cells: Ambient: 7 days; Refrigerated: 14 days; Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis, Grossly lipemic, Plasma.
Methodology
Immunoassay
Setup Schedule
Monday & Wednesday & Friday
Report Available
1-4 days
Reference Range
Index Interpretation
<0.90 Negative
0.90-1.09 Equivocal
>1.09 Positive
This assay utilizes recombinant type-specific antigens to differentiate HSV-1 from HSV-2 infections. A index positive result cannot distinguish between recent and past infection. If recent HSV infection is suspected but the results are negative or equivocal, the assay should be repeated in 4-6 weeks. The performance index characteristics of the assay have not been established for pediatric populations, immunocompromised patients, or neonatal screening.
<0.90 Negative
0.90-1.09 Equivocal
>1.09 Positive
This assay utilizes recombinant type-specific antigens to differentiate HSV-1 from HSV-2 infections. A index positive result cannot distinguish between recent and past infection. If recent HSV infection is suspected but the results are negative or equivocal, the assay should be repeated in 4-6 weeks. The performance index characteristics of the assay have not been established for pediatric populations, immunocompromised patients, or neonatal screening.
Clinical Significance
Herpes Simplex Virus 2 (IgG), Type-Specific Antibody - Herpes Simplex Virus (HSV) is responsible for several clinically significant human viral diseases, with severity ranging from inapparent to fatal. Clinical manifestations include genital tract infections, neonatal herpes, meningoencephalitis, keratoconjunctivitis, and gingivostomatitis. There are two HSV serotypes that are closely related antigenically. HSV type 2 is more commonly associated with genital tract and neonatal infections, while HSV type 1 is more commonly associated with infections of non-genital sites. Specific typing is not usually required for diagnosis or treatment. The mean time to seroconversion using the type specific assay is 25 days. The performance of this assay has not been established for use in a pediatric population, for neonatal screening, or for testing of immunocompromised patients.
Performing Laboratory
med fusion
